Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer
February 26 2021 - 8:00AM
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical
company engaged in the commercialization and development of
innovative anti-infective agents to treat serious infections, today
announced the appointment of Daniel Dolan as Chief Financial
Officer (CFO), effective close of business March 12, 2021. Mr.
Dolan will replace current CFO Gary Sender, who is retiring from
Nabriva. Mr. Sender will serve as a consultant for Nabriva at least
through the remainder of 2021 to support Mr. Dolan’s transition
into the CFO role.
“We are very pleased to have Dan join our leadership team. Dan
is a seasoned business leader and well-rounded finance executive
with a demonstrated track record in the biopharmaceutical
industry,” said Ted Schroeder, Chief Executive Officer of Nabriva
Therapeutics. “His proven expertise in financial planning and
analysis, accounting, capital financing, and investor relations,
combined with his knowledge of research and development,
manufacturing, and commercial operations, makes him an ideal
executive to assume the CFO mantle.”
Mr. Dolan brings more than 20 years of global, corporate finance
and executive management experience to his role at Nabriva. Most
recently, he served as principal financial officer of Radius
Health, Inc., a commercial stage biopharmaceutical company
developing endocrine therapeutics, where he was responsible for all
aspects of finance, business planning and analysis, investor
relations, procurement, and facilities. As a member of the
executive leadership team, he spearheaded operational improvements
that drove growth in the company’s existing portfolio of pipeline
assets. He joined Radius in 2017 as vice president of finance.
Before that, Mr. Dolan had a 12-year career at Shire
Pharmaceuticals (acquired by Takeda Pharmaceutical Company in
2019), where he held multiple finance positions of increasing
responsibility during his tenure at the company. Most recently, he
served as vice president, finance-global product strategy, where he
was the finance lead responsible for medium to long-term strategic
direction across Shire’s entire portfolio of products. Mr. Dolan
received his MBA and BS in Accounting from Widener University
(Chester, PA).
“I am honored to take the ball from Gary and join Nabriva as the
company pursues the development and commercialization of innovative
products that help patients address their unmet medical needs,”
said Mr. Dolan. “I look forward to contributing to the company’s
success by focusing on financial discipline and top line growth to
drive the business forward and increase shareholder value.”
About Nabriva Therapeutics plc
Nabriva Therapeutics is a biopharmaceutical company engaged in
the commercialization and development of innovative anti-infective
agents to treat serious infections. Nabriva Therapeutics received
U.S. Food and Drug Administration approval for XENLETA® (lefamulin
injection, lefamulin tablets), the first systemic pleuromutilin
antibiotic for community-acquired bacterial pneumonia (CABP).
Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for
injection, a potential first-in-class epoxide antibiotic for
complicated urinary tract infections (cUTI), including acute
pyelonephritis. Nabriva entered into an exclusive agreement with
subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to
market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the
United States and certain of its territories.
Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Nabriva Therapeutics, and other statements
containing the words “anticipate,” “believe,” “estimate,” “expect,”
“intend,” “may,” “plan,” “predict,” “project,” “target,”
“potential,” “likely,” “will,” “would,” “could,” “should,”
“continue,” and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: Nabriva Therapeutics’ ability to
successfully implement its commercialization plans for XENLETA and
whether market demand for XENLETA is consistent with its
expectations, Nabriva Therapeutics’ ability to build and maintain a
sales force for XENLETA, the content and timing of decisions made
by the U.S. Food and Drug Administration and other regulatory
authorities, the uncertainties inherent in the initiation and
conduct of clinical trials, availability and timing of data from
clinical trials, whether results of early clinical trials or
studies in different disease indications will be indicative of the
results of ongoing or future trials, uncertainties associated with
regulatory review of clinical trials and applications for marketing
approvals, the availability or commercial potential of CONTEPO for
the treatment of cUTI, the ability to retain and hire key
personnel, the availability of adequate additional financing on
acceptable terms or at all and such other important factors as are
set forth in Nabriva Therapeutics’ annual and quarterly reports and
other filings on file with the SEC. In addition, the
forward-looking statements included in this press release represent
Nabriva Therapeutics’ views as of the date of this press release.
Nabriva Therapeutics anticipates that subsequent events and
developments may cause its views to change. However, while Nabriva
Therapeutics may elect to update these forward-looking statements
at some point in the future, it specifically disclaims any
obligation to do so. These forward-looking statements should not be
relied upon as representing Nabriva Therapeutics’ views as of any
date subsequent to the date of this press release.
CONTACTS:
For InvestorsKim AndersonNabriva Therapeutics
plcIR@Nabriva.com
For MediaMike BeyerSam Brown
Inc.mikebeyer@sambrown.com312-961-2502
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Apr 2023 to Apr 2024